购物车
- 全部删除
- 您的购物车当前为空
Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities.
Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 期货 |
产品描述 | Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities. |
分子量 | 2293.78 |
分子式 | C96H177N39O24S |
CAS No. | 1164096-85-8 |
密度 | no data available |
存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容